KR20040103818A - Low-lactose milk and its production method - Google Patents
Low-lactose milk and its production method Download PDFInfo
- Publication number
- KR20040103818A KR20040103818A KR1020040085062A KR20040085062A KR20040103818A KR 20040103818 A KR20040103818 A KR 20040103818A KR 1020040085062 A KR1020040085062 A KR 1020040085062A KR 20040085062 A KR20040085062 A KR 20040085062A KR 20040103818 A KR20040103818 A KR 20040103818A
- Authority
- KR
- South Korea
- Prior art keywords
- milk
- lactose
- low
- sweetness
- galactose
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 93
- 239000008267 milk Substances 0.000 title claims abstract description 93
- 210000004080 milk Anatomy 0.000 title claims abstract description 93
- 239000008101 lactose Substances 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000001728 nano-filtration Methods 0.000 claims abstract description 14
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 17
- 229930182830 galactose Natural products 0.000 abstract description 17
- 239000008103 glucose Substances 0.000 abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 abstract 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 235000019192 riboflavin Nutrition 0.000 description 14
- 229960002477 riboflavin Drugs 0.000 description 14
- 239000002151 riboflavin Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000020190 lactose-free milk Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
Landscapes
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
Abstract
이 발명은 우유의 섭취 때문에 사람에게 일어나는 유당소화장애 증상을 방지하는 유당분해우유의 문제점인 감미를 감소시키기 위한 목적으로 우유를 가공하여 유당 함량을 감소시킨 저유당우유와 그 제조 방법이다. 본 발명에서 저유당우유은 우유 내 유당을 가수분해하여 생성된 포도당과 갈락토오스를 물리적으로 제거하여 감미를 감소시킨 유당분해우유이다.The present invention is a low lactose milk that has been processed to reduce the lactose content of milk for the purpose of reducing sweetness, which is a problem of lactose-decomposed milk that prevents the symptoms of lactose digestion disorders occurring in humans due to the consumption of milk and a method of producing the same. In the present invention, low lactose milk is lactose-decomposed milk which reduces sweetness by physically removing glucose and galactose produced by hydrolyzing lactose in milk.
구체적으로 우유를 유당분해효소로 처리하여 우유의 유당을 포도당과 갈락토오스로 가수분해하여 제조한 유당분해우유를 나노여과(nanofiltration)방법을 이용하여 포도당 및 갈락토오스를 부분적으로 제거하면서 농축한 후 물을 첨가하여 환원시켜 우유와 같은 감미를 가진 또는 감미가 더 적은 저유당우유의 제조 방법과 그 제품이다.Specifically, lactose-degraded milk prepared by treating milk with lactose by hydrolyzing milk lactose into glucose and galactose was concentrated while partially removing glucose and galactose by using nanofiltration method, and then water was added. The present invention provides a method for producing low-lactose milk having a sweetness or less sweetness, such as milk, and a product thereof.
Description
본 발명은 유당분해우유를 나노여과(nanofiltration) 방법으로 여과하여 농축한 후 가수하여 포도당과 갈락토오스의 농도를 감소시켜 감미를 감소시키는 반면에 칼슘과 리보플라빈의 손실을 15∼20% 이하로 만든 저유당우유와 그 제조방법에 관한 것이다.In the present invention, lactose-decomposed milk is filtered and concentrated by nanofiltration, followed by hydrolysis to reduce the concentration of glucose and galactose to reduce sweetness, while low lactose made of calcium and riboflavin less than 15-20%. It relates to milk and a method of manufacturing the same.
우유는 양질의 단백질, 칼슘 및 리보플라빈과 같은 필수 영양소를 함유하는 매우 영양학적으로 중요한 식품이다. 우유에는 탄수화물로서 유당을 4.8∼5.2% 함유하고 있으며 우유를 섭취하면 유당은 소장 내 점막에 위치한 유당분해효소에 의해 포도당과 갈락토오스로 분해되어 소화 흡수된다.Milk is a very nutritionally important food containing essential nutrients such as high quality protein, calcium and riboflavin. Milk contains 4.8-5.2% of lactose as carbohydrates. When milk is ingested, lactose is digested and digested into glucose and galactose by lactose enzymes located on the mucous membranes of the small intestine.
그러나 일부 서양인을 포함하여 대부분의 동양인과 흑인은 유아기를 지나 이유된 후에 성장하면서 소장 내 유당분해효소가 급격히 감소하여 유당분해능력이 결핍하게 된다(J. Am. Col. Nutr., 19, 165S (2000) : J. Am. Col. Nutr., 20, 198S (2001) : J. Pediatr. Gastroenterol. Nutr., 30, 283 (2000): 한국낙농학회지,16, 105(1994)). 따라서 대체로 200㎖(약 10g의 유당을 함유) 정도의 우유는 대부분의 사람에게 유당소화장애 증상들이 일어나지 않지만 유당을 20∼50g 이상을 공복에 섭취하면 유당분해능력이 결핍된 사람에게 이 증상이 일어난다. 유당소화장애 증상은 우유를 섭취할 경우에 소장 내에서 유당이 소화 흡수되지 않아 대장내로 유입되어 장내 삼투압의 증가에 의한 수분의 흡수 억제 및 대장균 등의 증식에 의하여 산도의 증가, 가스 및 독소의 생성에 의한 분변의 연성화, 가스의 배출 및 설사를 유발하게 된다. 이러한 증상들을 경험한 사람은 우유의 섭취를 기피하는 중요한 원인의 하나가 되고 있다. 성장기의 청년과 성인들의 우유의 섭취량 감소는 칼슘의 공급부족으로 인한 신체적 성장의 억제 및 골다공증을 유발할 수 있다.However, most Asians and blacks, including some Westerners, grow after weaning after weaning, resulting in a rapid decrease in lactose in the small intestine, resulting in a lack of lactose-degrading capacity (J. Am. Col. Nutr., 19, 165S ( 2000): J. Am. Col. Nutr., 20, 198S (2001): J. Pediatr.Gastroenterol.Nutr., 30, 283 (2000): Korean Journal of Dairy Science, 16, 105 (1994)). Therefore, milk of about 200ml (containing about 10g of lactose) does not cause lactose digestion symptoms in most people, but this symptom occurs in people who are lactose deficient if they consume 20-50g or more of lactose on an empty stomach. . The symptoms of lactose digestion disorders are that when milk is ingested, lactose is not digested and absorbed in the small intestine, so it enters the large intestine, inhibits the absorption of water by increasing the intestinal osmotic pressure, and increases the acidity, gas, and toxin production by the growth of E. coli. Will cause softening of the feces, release of gas and diarrhea. People who experience these symptoms are one of the major reasons for avoiding milk. Reduced milk intake in young adults and adults during growth can lead to inhibition of physical growth and osteoporosis due to lack of calcium.
유당소화장애가 있는 사람을 위하여 유당분해효소 또는 고정화 유당분해효소로 우유를 처리하여 유당을 포도당과 갈락토오스로 분해시켜 제조한 유당분해우유가 개발되어 생산되고 있다(U.S patent 5,357,852, (1994. 10. 25) : 김영교, 김영주, 김현욱, 우유 및 유제품의 과학, 선진문화사 (1981)194). 그러나 유당분해우유는 포도당과 갈락토오스를 함유하여 우유보다 단맛이 강하고 고온에서 가열 처리할 때에 갈변화반응이 촉진될 수 있고 신선한 맛이 감소하며 또한 삼투압이 높아 소화 생리에 적절하지 않아 소비가 촉진되지 못하고 있다.For those with lactose digestion disorders, lactose-degraded milk produced by treating milk with lactose or immobilized lactose by decomposing lactose into glucose and galactose has been developed and produced (US patent 5,357,852, (1994. 10. 25). ): Kim Young-kyo, Kim Young-ju, Kim Hyun-wook, Science of Milk and Dairy Products, Advanced Culture History (1981) 194). However, lactose-decomposed milk contains glucose and galactose, which is stronger than milk, can accelerate browning reaction when heated at high temperature, decreases fresh taste, and is not suitable for digestive physiology because of high osmotic pressure. have.
우유를 한외여과(ultrafiltration) 방법으로 여과하여 일부 유당을 제거한 후 물을 가하여 환원시킨 후 유당분해효소로 처리하여 무유당우유(U.S. patent 20030031754 (2003. 2. 13))를 개발되었다. 2001년에 Valio Ltd에서 유당을 물리적으로 완전히 제거한 무유당우유를 생산하였다(Tiina Mattila-Sandholm and MariaSaarela, Functional dairy products, Woodhead Publishing Ltd (2003) 9∼10). 그러나 한외여과 방법은 농축율에 따라 유당뿐만 아니라 우유 내 칼슘과 리보플라빈 등의 영양소가 상당히 제거되어 영양소의 상당한 손실이 있을 수 있다.Lactose-free milk (U.S. patent 20030031754 (February 13, 2003)) was developed by filtration of milk by ultrafiltration to remove some lactose, reducing it with water, and then treating it with lactose. In 2001, Valio Ltd produced lactose-free milk that physically completely eliminated lactose (Tiina Mattila-Sandholm and Maria Saarela, Functional dairy products, Woodhead Publishing Ltd (2003) 9-10). However, the ultrafiltration method may considerably remove nutrients such as calcium and riboflavin in milk as well as lactose, depending on the concentration, which may result in significant loss of nutrients.
막여과는 역삼투, 나노여과(nanofiltration), 한외여과, 미세여과 방법으로 구분된다. 우유의 당을 제거하고 단백질과 지방을 농축할 수 있는 방법으로서 나노여과와 한외여과를 이용할 수 있다. 나노여과는 분자량이 300 이상인 유기화합물과 칼슘, 마그네슘, 인산과 같은 다가이온을 농축한다(J. Membrane Sci. 98 : 249 (1995)). 한외여과는 분자량이 1,000∼1,000,000 이상인 물질을 농축할 수 있는 방법이다(E. Renner and M.H. ABD El-Salam, Application of ultrafiltration in the dairy industry, Elsevier Applied Science (1991) 9). 유당분해우유에 함유된 유당의 분자량이 354이고 포도당과 갈락토오스의 분자량이 180이고 리보플라빈의 분자량이 376이므로 나노여과를 이용하여 유당과 리보플라빈을 농축하고 포도당과 갈락토오스를 여과할 수 있다.Membrane filtration is classified into reverse osmosis, nanofiltration, ultrafiltration, and microfiltration. Nanofiltration and ultrafiltration can be used to remove sugar from milk and concentrate proteins and fats. Nanofiltration concentrates organic compounds with a molecular weight of 300 or more and polyvalent ions such as calcium, magnesium and phosphoric acid (J. Membrane Sci. 98: 249 (1995)). Ultrafiltration is a method that can concentrate substances with a molecular weight of 1,000 to 1,000,000 or more (E. Renner and M.H. ABD El-Salam, Application of ultrafiltration in the dairy industry, Elsevier Applied Science (1991) 9). Since the molecular weight of lactose in milk lactose is 354, the molecular weight of glucose and galactose is 180 and the molecular weight of riboflavin is 376, lactose and riboflavin can be concentrated using nanofiltration and the glucose and galactose can be filtered.
U.S. patent 20030031754(2003. 2. 13)에서 사용한 한외여과 방법에서 여과막이 우유의 유당을 여과시킨다. 이 방법은 분자량이 유사한 리보플라빈도 여과할 뿐만 아니라 칼슘의 상당량도 여과할 수 있다. 반면에 본 발명에서 나노여과 방법은 유당분해우유의 포도당과 갈락토오스을 여과하고 리보플라빈과 칼슘의 손실을 억제할 수 있는 장점이 있다.U.S. In the ultrafiltration method used in patent 20030031754 (February 13, 2003), a filtration membrane filters milk lactose. This method not only filters riboflavin with similar molecular weight, but can also filter significant amounts of calcium. On the other hand, in the present invention, the nanofiltration method has the advantage of filtering glucose and galactose of lactose-degraded milk and suppressing the loss of riboflavin and calcium.
따라서 본 발명의 목적은 나노여과 방법을 이용하여 유당분해우유를 1.5∼3배로 농축하여 포도당과 갈락토오스를 제거한 후 가수 환원하여 감미를 낮춤과 동시에 칼슘과 리보플라빈의 손실을 각각 15% 이하와 20% 이하로 최소화하여 저유당우유를 제조하는 것이다.Therefore, an object of the present invention is to concentrate lactose-decomposed milk 1.5 to 3 times using nanofiltration method to remove glucose and galactose, and then to reduce the sweetness by reducing the sweetness while reducing the loss of calcium and riboflavin 15% or less and 20% or less, respectively. By minimizing the production of low lactose milk.
도 1은 저유당우유의 일반적인 제조 공정도1 is a general manufacturing process of low lactose milk
본 발명의 구성은 우유에 유당분해효소를 첨가하여 일정한 온도와 시간에서 반응시켜 제조한 유당분해우유를 나노여과 방법으로 농축시킨 후 물을 가하여 저유당우유를 제조한다. 도 1에 일반적인 저유당우유의 제조 방법을 제시하였다. 유당분해우유의 위생적 품질이 열등하거나 유방분해효소 처리시 반응 온도가 높은 경우 우유를 가열하여(예: 65℃, 30분) 살균하고 우유내 효소를 불활성화 한다(선택 가능 단계). 적절한 유당분해효소를 우유에 첨가하여 일정한 온도와 시간 동안 반응시켜 유당을 포도당과 갈락토오스로 분해시킨다. 유당분해우유를 가열하여 (예: 65℃, 30분) 유당분해효소를 불활성화한다(선택 가능 단계). 이미 살균 처리하였고 유당 분해를 중단할 필요가 없는 경우 가열할 필요가 없다. 여과와 청정은 우유 내 이물질을 제거하기 위하여 우유를 여과하거나 원심분리하는 공정이다. 균질은 우유의 지방을 분산시켜 크림의 분리를 방지하는 공정으로서 제품의 종류에 따라 선택하여 사용할 수 있으며 살균 처리 전후에 시행할 수 있다(선택 가능 단계).In the constitution of the present invention, lactose-degraded milk prepared by adding lactose to the milk and reacting at a constant temperature and time is concentrated by a nanofiltration method and then water is added to prepare low lactose milk. 1 shows a general low lactose milk production method. If the hygienic quality of lactose-degraded milk is inferior or the reaction temperature is high during mammary enzyme treatment, the milk is heated (eg, 65 ° C., 30 minutes) to sterilize and inactivate the enzyme in the milk (optional step). Appropriate lactose is added to milk and allowed to react for a certain temperature and time to break down lactose into glucose and galactose. Lactose digested milk is heated (eg 65 ° C., 30 minutes) to inactivate lactose enzymes (selectable step). If it has already been sterilized and there is no need to stop lactose decomposition, it does not need to be heated. Filtration and clarification are the processes in which milk is filtered or centrifuged to remove foreign substances in the milk. Homogeneous is a process of dispersing milk fat to prevent the separation of cream, can be selected according to the type of product and can be carried out before and after sterilization treatment (optional step).
나노여과 여과장치에 유당분해우유를 유입시킬 때에 여과막 제조회사에서 제시한 온도이하에서 가동하는데 가급적 온도가 높아야 여과액의 방출유량이 높다. 우유의 유입 유량과 압력은 여과막 제조회사가 제시한 조건을 준수하며 여과액 유량이 높도록 최적 조건을 결정하여 사용한다. 유당 분해정도에 따라 유당분해우유를 1.5∼3배 정도 농축한 후 가수하여 일정한 부피로 환원시켜 신선한 우유와 같은 감미를 같게 하거나 감미를 더 줄일 수도 있다. 여과와 가수 및 환원 중에 오염이 일어날 수 있으므로 우유를 LTLT(65℃, 30분), HTST(73℃, 15초), 또는 UHT(130℃, 2초) 살균한 후 청결한 용기에 충전하여 저유당우유를 제조한다. 멸균우유일 경우 UHT 살균한 후 무균상태에서 살균된 용기에 충전한다.When the lactose-decomposed milk is introduced into the nanofiltration filtration device, it operates at a temperature lower than that suggested by the filtration membrane manufacturer. The flow rate and pressure of milk comply with the conditions suggested by the filter membrane manufacturer, and the optimum conditions are determined and used so that the filtrate flow rate is high. Depending on the degree of lactose decomposition, lactose-decomposed milk may be concentrated to 1.5 to 3 times and then hydrolyzed to reduce to a certain volume so that the sweetness is the same as fresh milk or the sweetness may be further reduced. Contamination may occur during filtration, hydrolysis, and reduction, so that milk can be sterilized in LTLT (65 ° C, 30 minutes), HTST (73 ° C, 15 seconds), or UHT (130 ° C, 2 seconds), and then filled into clean containers and low lactose Prepare milk. In case of sterile milk, sterilize UHT and fill it into sterilized containers in aseptic condition.
[실시예]EXAMPLE
우유에 유당분해효소(Validase, Valley Research, Inc.)를 0.03%를 가하여 4℃에서 24시간 반응시킨 후 65℃에서 30분간 가열하여 효소를 불활성화하고 살균하여 유당분해우유를 제조하였다. 유당분해우유를 나노여과 여과막(DL4040F1020, Osmonics)을 이용하여 40℃에서 150psi의 압력으로 농축하였다. 이때 유당분해우유의 유입유량은 약 35ℓ/분이고 여과액의 방출유량은 약 1.8ℓ/분이었다. 유당분해우유가 2배와 2.5배 농축되었을 때에 농축된 유당분해우유와 여과액의 시료를 채취하였다.Lactobacillus (Validase, Valley Research, Inc.) was added 0.03% to the milk and reacted at 4 ° C for 24 hours, followed by heating at 65 ° C for 30 minutes to inactivate and sterilize lactose-degraded milk. Lactose digested milk was concentrated using a nanofiltration filtration membrane (DL4040F1020, Osmonics) at a pressure of 150 psi at 40 ° C. At this time, the flow rate of lactose-decomposed milk was about 35 L / min and the discharge flow rate of the filtrate was about 1.8 L / min. Lactose digested milk and filtrate samples were collected when lactose digested milk was concentrated 2 and 2.5 times.
농축된 유당분해우유에 물을 가하여 유당분해우유의 원래 부피가 되게 환원하여 저유당우유를 제조하였다. 관능검사에서 15℃로 조정한 저유당우유와 우유의 감미를 비교하였다. 저유당우유를 비롯하여 우유 및 유당분해우유의 수분(상압건조법), 유지방(Gerber 방법), 조단백질(Kjeldahl 방법), 조회분(건식회화법), 유당, 포도당 및 갈락토오스(HPLC 방법), 칼슘 및 나트륨(원자흡광법), 리보플라빈(HPLC 방법)을 정량분석하였다.Low lactose milk was prepared by adding water to the concentrated lactose-degraded milk to the original volume of the lactose-decomposed milk. The sensory test was performed to compare the sweetness of milk with low lactose milk adjusted to 15 ℃. Moisture (atmospheric drying), milk fat (Gerber method), crude protein (Kjeldahl method), crude ash (dry calcification method), lactose, glucose and galactose (HPLC method), calcium and sodium (Atomic absorption) and riboflavin (HPLC method) were quantitatively analyzed.
관능검사에 참석한 6명 중 5명이 2배 농축 후 가수 환원한 저유당우유가 우유보다 감미가 더 강하다고 응답하였으며 1명은 우유가 감미가 더 강하다고 응답하였다. 우유가 2.5배 농축 후 가수 환원한 저유당우유보다 감미가 더 강하다고 6명 모두 응답하였다. 따라서 우유와 유사한 감미를 가진 저유당우유는 약 2∼2.5배 농축한 후 환원시킨 우유라고 할 수 있었다.Five of the six participants who participated in the sensory test responded that low-lactose milk, which had been reduced after doubling, was sweeter than milk, and one responded that milk was more sweet. All six responded that the milk was sweeter than the low-lactose milk, which had been reduced and reduced by 2.5 times. Therefore, low-lactose milk with a sweetness similar to milk could be said to be reduced milk after concentration of 2 to 2.5 times.
표 1에서와 같이 유당분해우유의 유당 농도가 0.8%로서 우유 내 유당의 약 84%가 분해되었다. 이 유당 농도는 법적 기준(축산물의 가공 기준 및 성분규격, 국립수의과학검역원 (2001) 18∼19)인 1.0% 이하이었다. 저유당우유의 수분함량이 유당분해우유보다 1.5∼2.1%가 더 높았으며 유지방, 조단백질, 유당의 변화는 적었다. 2배 농축 후 가수 환원한 저유당우유가 유당분해우유에 비해 포도당, 갈락토오스 및 나트륨의 농도의 비율이 각각 68%, 71% 및 68% 이었다. 반면에 칼슘과 리보플라빈은 93% 및 90%이었다. 그리고 2.5배 농축 후 가수 환원한 저유당우유가 유당분해우유에 비해 포도당, 갈락토오스 및 나트륨의 농도가 각각 55%, 59% 및 61% 이었다. 반면에 칼슘과 리보플라빈은 90% 및 86% 이었다. 이 결과로부터 나노여과 방법에 의해 포도당, 갈락토오스 및 나트륨에 비해 칼슘과 리보플라빈이 선택적으로 농축되었음을 알 수 있었다. 따라서 우유와 감미가 유사한 저유당우유가 유당분해우유에 비해 칼슘은 최소 90% 이상 그리고 리보플라빈은 최소 85%, 이상의 농도를 유지할 수 있었다.As shown in Table 1, the lactose concentration of lactose-degraded milk was 0.8% and about 84% of the lactose in the milk was decomposed. The lactose concentration was 1.0% or less, which is a legal standard (processing standard and ingredient standard of livestock products, National Veterinary Research and Quarantine Service (2001) 18-19). The water content of low lactose milk was 1.5-2.1% higher than that of lactose-degraded milk and the changes of milk fat, crude protein and lactose were small. The low-lactose milk hydrolyzed after 2 times concentration was 68%, 71% and 68% of the concentrations of glucose, galactose and sodium, respectively, compared to lactose-degraded milk. Calcium and riboflavin, on the other hand, were 93% and 90%. The low-lactose milk, which had been hydrolyzed after 2.5-fold concentration, had a concentration of 55%, 59% and 61% of glucose, galactose and sodium, respectively, as compared to lactose-degraded milk. On the other hand, calcium and riboflavin were 90% and 86%. From these results, it can be seen that calcium and riboflavin were selectively concentrated in comparison with glucose, galactose and sodium by the nanofiltration method. Therefore, low lactose milk with similar sweetness to milk could maintain at least 90% calcium and at least 85% riboflavin compared to lactose-degraded milk.
본 발명은 유당분해우유의 감미 성분인 포도당과 갈락토오스를 나노여과 방법으로 제거하여 만든 저유당우유가 유당소화장애에 의한 질환을 예방할 수 있을 뿐만 아니라 감미가 적고 이취가 적어 기호도가 높아 전반적인 우유의 소비를 증대시킬 것으로 기대된다. 본 발명에서 사용한 나노여과 방법을 이용할 때에 우유의 중요 영양분인 칼슘과 리보플라빈의 손실을 각각 최소 15% 및 20%, 이하로 유지하여 손실을 최소화할 수 있다.In the present invention, low lactose milk made by removing glucose and galactose, which are sweet components of lactose-decomposed milk, can be prevented from diseases caused by lactose digestion disorder as well as low sweetness and less off-flavor, resulting in high overall milk consumption. It is expected to increase. When using the nanofiltration method used in the present invention, loss of calcium and riboflavin, which are important nutrients in milk, can be kept at least 15% and 20%, respectively, to minimize the loss.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040085062A KR20040103818A (en) | 2004-10-19 | 2004-10-19 | Low-lactose milk and its production method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040085062A KR20040103818A (en) | 2004-10-19 | 2004-10-19 | Low-lactose milk and its production method |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20040103818A true KR20040103818A (en) | 2004-12-09 |
Family
ID=37379656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040085062A KR20040103818A (en) | 2004-10-19 | 2004-10-19 | Low-lactose milk and its production method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20040103818A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011801A1 (en) * | 2006-07-17 | 2008-01-31 | Shanghai Shanglong Dairy Co., Ltd. | Method for making lactose-removing milk |
WO2009043877A1 (en) * | 2007-10-01 | 2009-04-09 | Parmalat Spa | Method to obtain milk with low sugar content |
US20100055286A1 (en) * | 2008-08-29 | 2010-03-04 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
WO2010008865A3 (en) * | 2008-06-24 | 2010-04-15 | Sizer Charles E | Process for making a shelf-stable milk based beverage concentrate |
WO2010119439A1 (en) * | 2009-04-15 | 2010-10-21 | Bopa Ireland Limited | A reduced lactose milk product and a process for the preparation thereof |
KR101027187B1 (en) * | 2007-07-28 | 2011-04-05 | 동국대학교 산학협력단 | Sweet milk production method and sweet milk produced therefrom |
US8445052B2 (en) | 2007-10-03 | 2013-05-21 | Arla Foods Amba | Process for producing lactose-free milk |
AU2009286575B2 (en) * | 2008-08-29 | 2015-04-30 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
RU2654592C2 (en) * | 2013-07-17 | 2018-05-21 | Компани Жервэ Данон | Process for preparing fermented dairy product with reduced content of lactose and improved nutritional and organoleptic properties |
US10080372B2 (en) | 2008-08-29 | 2018-09-25 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
US10952449B2 (en) | 2014-09-09 | 2021-03-23 | David F. Paolella | Gas infused milk product and method of making the same |
-
2004
- 2004-10-19 KR KR1020040085062A patent/KR20040103818A/en not_active Application Discontinuation
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011801A1 (en) * | 2006-07-17 | 2008-01-31 | Shanghai Shanglong Dairy Co., Ltd. | Method for making lactose-removing milk |
US8580323B2 (en) | 2006-07-17 | 2013-11-12 | Shanghai Shanglong Dairy Co., Ltd. | Method for making lactose removed milk |
KR101122928B1 (en) * | 2006-07-17 | 2012-03-20 | 상하이 상롱 다이어리 컴퍼니 리미티드 | Method for making lactose-removing milk |
KR101027187B1 (en) * | 2007-07-28 | 2011-04-05 | 동국대학교 산학협력단 | Sweet milk production method and sweet milk produced therefrom |
WO2009043877A1 (en) * | 2007-10-01 | 2009-04-09 | Parmalat Spa | Method to obtain milk with low sugar content |
US8445052B2 (en) | 2007-10-03 | 2013-05-21 | Arla Foods Amba | Process for producing lactose-free milk |
US9265269B2 (en) | 2008-06-24 | 2016-02-23 | Dairyvative Technologies, Llc | Process for making a shelf-stable milk based beverage concentrate |
WO2010008865A3 (en) * | 2008-06-24 | 2010-04-15 | Sizer Charles E | Process for making a shelf-stable milk based beverage concentrate |
CN102105066A (en) * | 2008-06-24 | 2011-06-22 | 查尔斯·E·信泽尔 | Process for the preparation of shelf-stable milk-based beverage concentrates |
US8986768B2 (en) | 2008-08-29 | 2015-03-24 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
AU2009286575B2 (en) * | 2008-08-29 | 2015-04-30 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
US20100055286A1 (en) * | 2008-08-29 | 2010-03-04 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
US10080372B2 (en) | 2008-08-29 | 2018-09-25 | Valio Ltd. | Low-lactose and lactose-free milk product and process for production thereof |
GB2481169B (en) * | 2009-04-15 | 2013-08-21 | Bopa Ireland Ltd | A reduced lactose milk product and a process for the preparation thereof |
GB2481169A (en) * | 2009-04-15 | 2011-12-14 | Bopa Ireland Ltd | A reduced lactose milk product and a process for the preparation thereof |
WO2010119439A1 (en) * | 2009-04-15 | 2010-10-21 | Bopa Ireland Limited | A reduced lactose milk product and a process for the preparation thereof |
US9167824B2 (en) | 2009-04-15 | 2015-10-27 | Glanbia Nutritionals (Ireland) Limited | Process for the preparation of a reduced lactose milk product |
RU2654592C2 (en) * | 2013-07-17 | 2018-05-21 | Компани Жервэ Данон | Process for preparing fermented dairy product with reduced content of lactose and improved nutritional and organoleptic properties |
US10952449B2 (en) | 2014-09-09 | 2021-03-23 | David F. Paolella | Gas infused milk product and method of making the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100901012B1 (en) | Manufacturing method of lactose-free dairy | |
JP6693807B2 (en) | Dairy products and methods of preparation | |
US8449938B2 (en) | Lactose-free milk product and processes for producing the same | |
DK2050341T3 (en) | Process for the preparation of lactose-free milk | |
EP3471561B1 (en) | Process for production of improved nutritional products containing milk protein and milk saccharides | |
EP0531142B1 (en) | Hypoallergenic milk products from natural and/or synthetic components and process of manufacture | |
CN102595915A (en) | Whey protein product and a method for its preparation | |
KR20040103818A (en) | Low-lactose milk and its production method | |
US20010022986A1 (en) | Dairy permeate-based beverage | |
RU2555522C1 (en) | Complex milk salt, its production method and food products containing such salt | |
CN112423596B (en) | Production and separation of milk fractions using forward osmosis | |
US5912040A (en) | Process of making a dairy permeate-based beverage | |
CN112646847A (en) | Preparation method of galactose glucose mixture | |
CN215873298U (en) | Apparatus system for preparing dairy products | |
CN112088942A (en) | Strained dairy product added with quinoa particles and preparation method thereof | |
CN107760738A (en) | The extracting method of oligosaccharide | |
CN112931620A (en) | Device system and method for preparing dairy product | |
JPH0145354B2 (en) | ||
AU770468B2 (en) | Method of producing compositions containing polyamines | |
JPH0145353B2 (en) | ||
CN1557476A (en) | Multiple biological activity polypeptide nutrient | |
CN115175566B (en) | Production and separation of milk fractions with final nanofiltration step | |
KR20230089152A (en) | Preparation method for lactose free milk with improved digestibility and stability, and milk, fermented milk, beverage composition and liquid modified milk for baby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20041019 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20051215 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20060406 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20051215 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20060427 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20051215 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |